Ustekinumab – Treatment for Plaque Psoriasis

 

Key Data:

Drug (Brand/Generic)
Ustekinumab (CNTO 1275)
Company/Licensee
Centocor and Janssen-Cilag
Therapy Class
MAb
Product Description
Human anti-IL-12 and anti-IL-23 MAb
Current Indication
Moderate-to-severe plaque psoriasis
Market Sector
Dermatology
Development Status
Approved US and EU



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development